secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2023-09-25T23:59:59+00:00
Accession:  0001213900-23-078887
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed receives Nasdaq minimum bid price deficiency notice; 180 days to cure
---------------------------------------------------------------------------

- Nasdaq notified InMed on Sept 19, 2023, that average closing bid price was below $1.00 for 30 consecutive trading days.
- Company has 180 calendar days from notice to regain compliance under Nasdaq Listing Rule 5550(a)(2).
- No immediate impact on listing; shares continue trading under 'INM' pending cure or appeal.
- If not cured, Nasdaq may delist; InMed can appeal to a Hearings Panel with continued trading pending appeal.
- No assurance that cure or appeal will be successful.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390023078887/0001213900-23-078887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390023078887/ea185699-8k_inmedpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-078887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer